Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately-held Texas biotech gets $35 million upfront from Kyowa Hakko Kirin and sets its sights on a 2011 NDA filing in the U.S.